Synthetic digital twins - the future of healthcare

Part of the “Synthetic Data in Healthcare” blog series by Aindo.

 

Imagine being able to simulate how a patient will respond to a treatment in a fully virtual environment. With synthetic digital twins, this vision is coming closer to reality.

In the final post of our series, we explore how synthetic data is laying the foundation for digital twins in healthcare – AI-powered virtual patients that could transform precision medicine, clinical trials, and care delivery.

What is a digital twin?

A digital twin is a virtual model that mirrors a real-world system. In industry, digital twins have been used for years to simulate complex systems – for example, a digital twin of an aircraft is a dynamic virtual replica that is continuously updated with real-time sensor data. Engineers use this live digital model to test scenarios, detect anomalies, optimize performance, and even predict maintenance needs before problems occur.

In healthcare, the ambition is even greater: to build a realistic, dynamic model of a person’s health, including conditions, treatments, and outcomes.

These digital twins could eventually:

• Predict disease progression.
• Simulate drug responses.
• Optimize treatment plans.
• Enable fully virtual clinical trials.

But building digital twins requires rich, diverse, and compliant data – something the healthcare system still struggles to provide.

How synthetic data powers digital twins in healthcare

Real patient data is often fragmented, incomplete, or inaccessible due to privacy concerns. That’s where synthetic data comes in: it provides high-fidelity datasets that reflect the complexity of real patient journeys, without exposing identifiable information.

Because synthetic data can replicate real-world variability, correct demographic imbalances, and scale beyond consent-restricted datasets, it forms a powerful foundation for building digital twins. The result is a virtual patient model that is both scientifically robust and operationally flexible.

From synthetic cohorts to personalized digital twins

The journey starts with synthetic cohorts – statistically representative populations generated for research, AI training, or the creation of synthetic external control arms in clinical trials. These cohorts allow teams to explore trends, identify risk factors, or test algorithm performance without relying on protected health data.

As modeling advances, we can move toward personalized digital twins: virtual replicas that capture a patient’s unique clinical characteristics. Such twins could allow clinicians to test treatment strategies in silico before applying them in practice, anticipate complications, or simulate disease progression under different scenarios. The result is a safer, faster, and more adaptive approach to care.

Applications on the horizon

Synthetic-data-powered digital twins have the potential to transform multiple areas of healthcare research and delivery, including:

• Drug development, by reducing trial size and duration through synthetic control arms and virtual experimentation.
• Precision medicine, by identifying the optimal treatment pathway for individual patients based on simulated outcomes.
• Clinical trials, by enabling adaptive, virtual-first trial designs that reduce patient burden and accelerate enrollment.
• Public health, by modeling outbreaks, resource needs, and intervention impacts at population scale.

Regulatory pathways are opening

Italy’s landmark AI law (Articles 8 and 9) explicitly supports synthetic data for healthcare research, paving the way for innovations like digital twins. At the European level, regulatory sandboxes and frameworks such as the Europrivacy certification offer compliant routes for experimentation and validation of this emerging technology.

Aindo’s vision

At Aindo, we see synthetic digital twins as the next frontier of responsible AI in healthcare. Our advanced generative AI models learn clinical patterns across time, patient subgroups, and disease trajectories. By combining this capability with rigorous privacy and regulatory alignment, we are building the technological foundation for safe, ethical, and future-ready virtual patient systems.

We are already partnering with research institutes, hospitals, and life-sciences companies on digital-twin initiatives. For example, in our work on synthetic digital twins for Parkinson’s disease, we help researchers model deep-phenotyped synthetic patients to identify which subgroups may benefit most from specific therapies - a first step toward true precision medicine.

The future is closer than you think.

Let’s shape the future of healthcare together

Are you a researcher, clinician, policymaker, or innovator interested in building the next generation of healthcare?

Let’s connect and explore your vision.

Missed the rest of the series? Catch up with our previous blogs on AI development in healthcare, real-world evidence, and clinical trials.